Literature DB >> 3532219

Calcitonin gene-related peptide (CGRP): perivascular distribution and vasodilatory effects.

R Uddman, L Edvinsson, E Ekblad, R Håkanson, F Sundler.   

Abstract

The distribution of perivascular nerve fibers displaying calcitonin gene-related peptide (CGRP) immunoreactivity and the effect of CGRP on vascular smooth muscle were studied in the guinea-pig. Perivascular CGRP fibers were seen in all vascular beds. Generally, they were more numerous around arteries than veins. Small arteries in the respiratory tract, gastrointestinal tract and genitourinary tract had numerous CGRP fibers. The gastroepiploic artery in particular received a rich supply of such fibers. Coronary blood vessels had a moderate supply of CGRP fibers. In the heart, a moderate number of CGRP fibers was seen running close to myocardial fibers. The atria had a richer supply than the ventricles. Numerous CGRP immunoreactive nerve cell bodies and nerve fibers were seen in sensory (trigeminal, jugular and spinal dorsal root) ganglia. Sequential or double immunostaining with antibodies against substance P and CGRP suggested co-existence of the two peptides in nerve cell bodies in the ganglia and in perivascular fibers. In agreement with previous findings CGRP turned out to be a strong vasodilator in vitro as tested on several blood vessels (e.g. basilar, gastroepiploic and mesenteric arteries). Conceivably, perivascular CGRP/SP fibers have a dual role as regulator of local blood flow and as carrier of sensory information.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3532219     DOI: 10.1016/0167-0115(86)90071-6

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  66 in total

Review 1.  Chemical mediators of migraine: preclinical and clinical observations.

Authors:  Saurabh Gupta; Stephanie J Nahas; B Lee Peterlin
Journal:  Headache       Date:  2011-06       Impact factor: 5.887

2.  Involvement of capsaicin-sensitive neurones in the haemodynamic effects of exogenous vasoactive peptides: studies in conscious, adult Long Evans rats treated neonatally with capsaicin.

Authors:  H Bachelard; S M Gardiner; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

3.  Distribution of calcitonin gene-related peptide immunoreactivity in the central nervous system of the frog, Rana esculenta.

Authors:  M Petkó; A Sánta
Journal:  Cell Tissue Res       Date:  1992-09       Impact factor: 5.249

4.  Vasodilating effects of human and rat calcitonin gene-related peptides in isolated porcine coronary arteries.

Authors:  T Shoji; H Ishihara; T Ishikawa; A Saito; K Goto
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-10       Impact factor: 3.000

Review 5.  The role of neuropeptides in cardiovascular regulation.

Authors:  D Ganten; M Paul; R E Lang
Journal:  Cardiovasc Drugs Ther       Date:  1991-02       Impact factor: 3.727

6.  Calcitonin gene-related peptide (CGRP) causes redistribution of blood flow in humans.

Authors:  K Jäger; R Muench; H Seifert; C Beglinger; A Bollinger; J A Fischer
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

7.  Calcitonin gene-related peptide in rat arterial and venous vessels: sensitivity to capsaicin, bradykinin and FMLP.

Authors:  E Del Bianco; F Perretti; M Tramontana; S Manzini; P Geppetti
Journal:  Agents Actions       Date:  1991-11

8.  Human alpha-calcitonin gene-related peptide (CGRP) is a potent vasodilator in human mesenteric vasculature.

Authors:  I Marshall; S J Al-Kazwini; J J Holman; R K Craig
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

9.  Electrophysiological effects of activating the peptidergic primary afferent innervation of rat mesenteric arteries.

Authors:  W R Dunn; T A Hardy; J A Brock
Journal:  Br J Pharmacol       Date:  2003-08-04       Impact factor: 8.739

Review 10.  Calcitonin gene-related peptide (CGRP) and the pathophysiology of headache: therapeutic implications.

Authors:  L Edvinsson
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.